Simell Birgit, Jaakkola Teija, Lahdenkari Mika, Briles David, Hollingshead Susan, Kilpi Terhi M, Käyhty Helena
Vaccine Immunology Laboratory, National Public Health Institute, Mannerheimintie 166, 0300 Helsinki, Finland.
Clin Vaccine Immunol. 2006 Oct;13(10):1177-9. doi: 10.1128/CVI.00257-06. Epub 2006 Aug 23.
Pneumococcal neuraminidase, NanA, is a pneumococcal vaccine candidate. Prior culture-confirmed pneumococcal contacts were shown to induce serum anti-NanA antibodies during the first 2 years of life. The antibody concentrations at neither 12 nor 18 months were significantly associated with the risk of subsequent pneumococcal carriage or acute otitis media.
肺炎球菌神经氨酸酶NanA是一种肺炎球菌疫苗候选物。先前经培养确诊的肺炎球菌接触者在生命的头两年中会诱导产生血清抗NanA抗体。12个月和18个月时的抗体浓度均与随后发生肺炎球菌携带或急性中耳炎的风险无显著关联。